GNI Group (2160) Price & Analysis

Compare

3 Followers

2160 Stock Chart & Stats

¥2290.00

¥50.00(1.64%)

At close: Jan 08 4:00 PM EST

¥2290.00

¥50.00(1.64%)

Day’s Range― - ―

52-Week Range¥1,469.00 - ¥4,410.00

Previous CloseN/A

Volume492.20K

Average Volume (3M)969.16K

Market Cap

¥173.46B

Enterprise Value¥154.11B

Total Cash (Recent Filing)¥21.10B

Total Debt (Recent Filing)¥5.37B

Price to Earnings (P/E)―

Beta1.16

Next Earnings

May 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-74.44

Shares Outstanding55,685,127

10 Day Avg. Volume1,104,200

30 Day Avg. Volume969,156

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)2.52

Price to Sales (P/S)4.71

P/FCF Ratio-46.15

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)32.28

Revenue Forecast (FY)¥41.97B

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetLow debt relative to equity and expanding equity provide a durable financial buffer. This reduces refinancing and liquidity risk during cash burn, supports sustained R&D or capex funding, and gives management flexibility to execute strategy without immediate external funding pressure.

Multi-year Revenue GrowthA multi-year upward revenue trend indicates persistent end-market demand and an established market position. Over time this supports scale, potential operating leverage, and provides management room to focus on margin recovery and sustainable commercialization of offerings.

High Gross MarginsSustained high gross margins imply strong unit economics or pricing power in core products. Structurally healthy gross margins create a buffer against elevated operating costs and, if SG&A/R&D are optimized, can enable a credible path back to durable profitability and cash conversion.

Bears Say

Persistent Negative Cash FlowTwo consecutive years of negative operating and free cash flow show the business is not self-funding. Continued cash burn increases reliance on external capital, raising dilution or leverage risk and constraining long-term investments, commercial rollouts, and strategic optionality.

2025 Profitability CollapseA material swing to operating and net losses materially reduces earnings quality and threatens sustained viability if driven by recurring cost or demand issues. Restoring positive, predictable margins will likely require structural cost actions or stronger, persistent revenue expansion.

Volatile Growth And EarningsMarked volatility in revenue and EPS undermines forecastability and strategic planning. Persistent swings complicate partner/customer confidence and capital access, making long-term contracting, hiring, and investment decisions harder until performance stabilizes.

GNI Group News

GNI Group Wins Priority Review in China for Hepatitis B–Related Liver Fibrosis Drug

GNI Group ( ($JP:2160) ) just unveiled an update. GNI Group’s subsidiary Gyre Therapeutics has secured Priority Review...

8h ago

GNI Group Highlights Fibrosis Revenue Upside and Advances Degrader Pipeline via Gyre and Cullgen

An announcement from GNI Group ( ($JP:2160) ) is now available. GNI Group, through its U.S. affiliate Gyre...

5d ago

GNI Group Revises Parent-Only Results After Tax and Valuation Adjustments

GNI Group ( ($JP:2160) ) has provided an update. GNI Group Ltd. has announced corrections to previously disclosed...

14d ago

GNI Group Revamps Board Slate With New Independent Director Ahead of AGM

GNI Group ( ($JP:2160) ) has shared an update. GNI Group Ltd. has proposed a slate of director...

14d ago

GNI Group Revises FY2025 Results After Overstated CFC Tax Expense

An update from GNI Group ( ($JP:2160) ) is now available. GNI Group has announced a partial correction...

14d ago

GNI Group’s Gyre Therapeutics to acquire Cullgen in $300 million all-stock deal

An update from GNI Group ( ($JP:2160) ) is now available. GNI Group’s Nasdaq-listed subsidiary Gyre Therapeutics has...

15d ago

GNI Group Swings to Non-Consolidated Loss on Absence of One-Off Gain and Forward Transaction Hit

GNI Group ( ($JP:2160) ) has issued an update. GNI Group Ltd., a biopharmaceutical company listed on the...

1M ago

GNI Group Swings to Loss in FY2025 Despite Higher Revenue and Stronger Equity Base

GNI Group ( ($JP:2160) ) has issued an update. GNI Group reported FY2025 consolidated revenue of ¥26.84 billion,...

1M ago

GNI Group Delays 2026 Earnings Forecast Amid Regulatory and Pipeline Uncertainty

GNI Group ( ($JP:2160) ) has issued an update. GNI Group has postponed the disclosure of its full-year...

1M ago

GNI Group Explains Acquisition Plans, Earnings Revision and F351 Disclosure Strategy

GNI Group ( ($JP:2160) ) has issued an update. GNI Group has addressed a series of investor questions...

1M ago

2160 FAQ

What was GNI Group Ltd.’s price range in the past 12 months?

GNI Group Ltd. lowest stock price was ¥1469.00 and its highest was ¥4410.00 in the past 12 months.

What is GNI Group Ltd.’s market cap?

GNI Group Ltd.’s market cap is ¥173.46B.

When is GNI Group Ltd.’s upcoming earnings report date?

GNI Group Ltd.’s upcoming earnings report date is May 18, 2026 which is in 61 days.

How were GNI Group Ltd.’s earnings last quarter?

GNI Group Ltd. released its earnings results on Feb 13, 2026. The company reported -¥74.44 earnings per share for the quarter, missing the consensus estimate of ¥224.642 by -¥299.082.

Is GNI Group Ltd. overvalued?

According to Wall Street analysts GNI Group Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does GNI Group Ltd. pay dividends?

GNI Group Ltd. does not currently pay dividends.

What is GNI Group Ltd.’s EPS estimate?

GNI Group Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does GNI Group Ltd. have?

GNI Group Ltd. has 55,685,127 shares outstanding.

What happened to GNI Group Ltd.’s price movement after its last earnings report?

GNI Group Ltd. reported an EPS of -¥74.44 in its last earnings report, missing expectations of ¥224.642. Following the earnings report the stock price went down -3.49%.

Which hedge fund is a major shareholder of GNI Group Ltd.?

Currently, no hedge funds are holding shares in JP:2160

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

GNI Group Ltd.

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.